• +1-646-491-9876
    • +91-20-67278686

    Search

    Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017

    Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017

    • Report Code ID: RW0001767472
    • Category Pharmaceuticals
    • No. of Pages 90
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline landscape.

    Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache and shortness of breath. The predisposing factors include age, obesity and hormone therapy. Treatment includes surgery, chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 13 and 1 respectively.

    Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Paroxysmal Nocturnal Hemoglobinuria - Overview
    Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
    Achillion Pharmaceuticals Inc
    Akari Therapeutics Plc
    Alexion Pharmaceuticals Inc
    Alnylam Pharmaceuticals Inc
    Amgen Inc
    Apellis Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    ISU ABXIS Co Ltd
    Novartis AG
    NovelMed Therapeutics Inc
    Omeros Corp
    Ra Pharmaceuticals Inc
    Regeneron Pharmaceuticals Inc
    Regenesance BV
    Paroxysmal Nocturnal Hemoglobinuria - Drug Profiles
    ACH-4471 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALN-CC5 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALXN-1210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMY-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APL-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APL-9 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Coversin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GNR-045 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NM-9405 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-721 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-906 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RA-101348 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RA-101495 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Regenemab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-3918 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-6107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Factor D for PNH and Dense Deposit Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Factor D for Paroxysmal Nocturnal Hemoglobinuria and Membranoproliferative Glomerulonephritis Type II - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tesidolumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects
    Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products
    Paroxysmal Nocturnal Hemoglobinuria - Product Development Milestones
    Featured News & Press Releases
    Apr 24, 2017: Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
    Apr 06, 2017: Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
    Mar 30, 2017: Akari Therapeutics Announces FDA Fast Track Designation For Coversin
    Mar 21, 2017: USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
    Jan 06, 2017: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria
    Jan 03, 2017: Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
    Dec 20, 2016: Apellis Announces FDA Fast Track Designation for APL-2 in PNH
    Dec 05, 2016: Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases
    Dec 05, 2016: Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Dec 05, 2016: Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins
    Dec 04, 2016: New Data From ALXN1210 Dose-Escalation Study Presented At ASH Show Rapid And Sustained Reductions In LDH In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Dec 02, 2016: Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
    Nov 30, 2016: Ra Pharmaceuticals to Present Overview of RA101495 and Oral C5 Inhibitor at the International PNH Interest Group Annual Scientific Assembly
    Nov 21, 2016: Apellis to Present Safety and Efficacy Data from Clinical Trials of APL-2 in PNH at December Scientific Meetings
    Nov 17, 2016: Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Achillion Pharmaceuticals Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Akari Therapeutics Plc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amgen Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by ISU ABXIS Co Ltd, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Novartis AG, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by NovelMed Therapeutics Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Omeros Corp, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Ra Pharmaceuticals Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Regenesance BV, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects, H1 2017
    Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Achillion Pharmaceuticals Inc
    Akari Therapeutics Plc
    Alexion Pharmaceuticals Inc
    Alnylam Pharmaceuticals Inc
    Amgen Inc
    Apellis Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    ISU ABXIS Co Ltd
    Novartis AG
    NovelMed Therapeutics Inc
    Omeros Corp
    Ra Pharmaceuticals Inc
    Regeneron Pharmaceuticals Inc
    Regenesance BV

    Request for Sample

    Report Url http://www.reportsweb.com//paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments